Login / Signup

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.

Laura S GrahamLawrence D TrueRoman GulatiGeorge R SchadeJonathan WrightPetros GrivasTodd YezefskiKatie NegaKaterina AlexanderWen-Min HouEvan Y YuBruce MontgomeryElahe A MostaghelAlvin A MatsumotoBrett MarckNima SharifiWilliam J EllisNicholas P RederDaniel W LinPeter S NelsonMichael T Schweizer
Published in: The Prostate (2021)
In men with high-risk PC, pCR rates remained low even with combinatorial AR-directed therapy, although rates of MRD were higher. Ongoing follow-up is needed to validate clinical outcomes of men who achieve MRD.
Keyphrases
  • prostate cancer
  • middle aged
  • rectal cancer
  • radical prostatectomy
  • study protocol
  • clinical trial
  • lymph node
  • phase iii
  • phase ii
  • stem cells
  • randomized controlled trial
  • bone marrow
  • adipose tissue
  • drug delivery